$RIGL News

Rigel Pharmaceuticals Shares Rose Even As Profit Fell

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K

Rigel to Participate in Upcoming September Investor Conferences

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription

Rigel (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates